Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radio-/Chemotherapy for Pancreatic Adenocarcinoma
2009-011968-11Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- May 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Technische Universität Dresden. Primary endpoint: Standardized Uptake Value on PET-CT. Started May 2010; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2009-011968-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011968-11.